Jane Street Group LLC Takes Position in Cibus, Inc. (NASDAQ:CBUS)

Jane Street Group LLC purchased a new stake in shares of Cibus, Inc. (NASDAQ:CBUS) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 23,990 shares of the company’s stock, valued at approximately $67,000. Jane Street Group LLC owned 0.09% of Cibus as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of CBUS. IFP Advisors Inc bought a new stake in shares of Cibus in the 4th quarter worth approximately $36,000. Sei Investments Co. purchased a new position in Cibus in the fourth quarter worth about $49,000. XTX Topco Ltd purchased a new stake in Cibus during the fourth quarter valued at approximately $61,000. Commonwealth Equity Services LLC bought a new stake in Cibus during the fourth quarter valued at about $62,000. Finally, Barclays PLC grew its stake in shares of Cibus by 35.1% during the 4th quarter. Barclays PLC now owns 27,375 shares of the company’s stock valued at $76,000 after acquiring an additional 7,106 shares during the period. 33.81% of the stock is currently owned by hedge funds and other institutional investors.

Cibus Price Performance

NASDAQ:CBUS opened at $1.66 on Monday. The company has a 50 day moving average price of $2.18 and a 200-day moving average price of $2.57. Cibus, Inc. has a 1-year low of $1.40 and a 1-year high of $11.13. The firm has a market cap of $54.24 million, a price-to-earnings ratio of -0.07 and a beta of 1.88.

Cibus (NASDAQ:CBUS) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.04). Cibus had a negative return on equity of 28.17% and a negative net margin of 10,724.78%. The business had revenue of $1.03 million for the quarter, compared to analyst estimates of $1.15 million. On average, sell-side analysts anticipate that Cibus, Inc. will post -2.96 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Canaccord Genuity Group dropped their target price on shares of Cibus from $18.00 to $17.50 and set a “buy” rating for the company in a research report on Monday, May 12th. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of Cibus in a report on Friday, March 21st.

Cibus Profile

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.